Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
14 participants
INTERVENTIONAL
2009-11-30
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT02393209
A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer
NCT00717938
Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients
NCT00905983
A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)
NCT00916669
Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
NCT00801801
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm B: Enoxaparin
Enoxaparin
Arm A: No Enoxaparin
No Enoxaparin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enoxaparin
No Enoxaparin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women aged 18 and older
* Locally Advanced or Metastatic Non-small Cell Lung Cancer stage IIIB/IV without any previous therapy
* Life expectancy at least 12 weeks
* EOCG performance \< 1
* Appropriate renal and hepatic function
* Appropriate Hematology
* No bleeding events within 4 weeks prior to randomization
* No indication for prophylactic or therapeutic anticoagulation therapy
* Appropriate methods of contraception (both: men and women) for women of childbearing potential negative urine pregnancy test within 7 day prior to randomization
* Capability for s.c. injection of Enoxaparin every 24 hrs
Exclusion Criteria
* Known contraindication for Enoxaparin e.g. HIT,
* Known contraindication for Docetaxel, Cisplatin, Carboplatin or co-medication
* Participation in any other clinical trials within 30 days prior to randomization
* Any known medical condition that does not allow therapy according to study protocol
* Seizure disorder
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hannover Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolas Dickgreber, MD
Role: STUDY_CHAIR
Hannover Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hannover Medical School, Department of Pneumology
Hanover, Lower Saxonia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENOXA-NSCLC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.